The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Abstract
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Self-citationDavies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Self-citationAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Coombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., Van de Velde, C., Delozier, T., Alvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 907
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., Hilfrich, J., Kwasny, W., Menzel, C., Samonigg, H., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67059-6 · Cited by 879
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Self-citationAdjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Self-citationLoprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0926 · Cited by 733
Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., & Wolmark, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.517 · Cited by 714
Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013128213451 · Cited by 713
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 684
Self-citationExtending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 644
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., Watson, D., Geyer, C. E., Wickerham, D. L., & Wolmark, N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7610 · Cited by 619
Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R. L., Sandbach, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4028 · Cited by 588
Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 559
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810818 · Cited by 496
Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.159 · Cited by 478
Self-citationGnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Pristauz, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70122-x · Cited by 472
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2025 · Cited by 467
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
van Ramshorst, M. S., van der Voort, A., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Dezentjé, V. O., Oving, I. M., Honkoop, A. H., Tick, L. W., van de Wouw, A. J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30570-9 · Cited by 452
Gray, R. G., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., Poole, C. J., Bates, T., Chetiyawardana, S., Dewar, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.5 · Cited by 451
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., Paladini, G., Mesiti, M., Romeo, D., Rinaldini, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.120 · Cited by 445
Breast-cancer Adjuvant Therapy With Zoledronic Acid
Coleman, R. E., Marshall, H. C., Cameron, D., et al. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 413
Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., Fasching, P. A., Crown, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305488 · Cited by 405
Gralow, J. R., Burstein, H. J., Wood, W., Hortobagyi, G. N., Gianni, L., von Minckwitz, G., Buzdar, A. U., Smith, I. E., Symmans, W. F., Singh, B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3510 · Cited by 400
Self-citationGray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
Sgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
van de Velde, C. J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.-M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62312-4 · Cited by 372
Bradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00288-6 · Cited by 354
Self-citationDe Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S.-B., Bear, H., McCarthy, N., Melé Olivé, M., Gelmon, K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03639 · Cited by 326
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115858.45890.53 · Cited by 315
Jakesz, R., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., Mlineritsch, B., Tausch, C., Stierer, M., Hofbauer, F., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm246 · Cited by 312
Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.029 · Cited by 310
Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1858 · Cited by 308
Perez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., Shenkier, T. N., Tozer, R. G., Palmer, M. J., Shepherd, L. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4882 · Cited by 307
Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
Visvanathan, K., Chlebowski, R. T., Hurley, P., Col, N. F., Ropka, M., Collyar, D., Morrow, M., Runowicz, C., Pritchard, K. I., Hagerty, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5179 · Cited by 286
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M.-L., Simcock, R., Rea, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30650-6 · Cited by 286
Self-citationKaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., & von Minckwitz, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8054 · Cited by 267
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., Glaspy, J., Periañez, A. M., Tonkin, K., Deleu, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30687-4 · Cited by 261
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 259
Albain, K. S., Barlow, W. E., Ravdin, P. M., Farrar, W. B., Burton, G. V., Ketchel, S. J., Cobau, C. D., Levine, E. G., Ingle, J. N., Pritchard, K. I., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61523-3 · Cited by 258
Whelan, T. J., Goss, P. E., Ingle, J. N., Pater, J. L., Tu, D., Pritchard, K., Liu, S., Shepherd, L. E., Palmer, M., Robert, N. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.181 · Cited by 241
Jonat, W., Gnant, M., Boccardo, F., Kaufmann, M., Rubagotti, A., Zuna, I., Greenwood, M., & Jakesz, R. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70948-2 · Cited by 237
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02554 · Cited by 235
Self-citationBoccardo, F., Rubagotti, A., Guglielmini, P., Fini, A., Paladini, G., Mesiti, M., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl941 · Cited by 222
Sparano, J. A., Zhao, F., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9271 · Cited by 222
Smith, I. E., Dowsett, M., Yap, Y.-S., Walsh, G., Lønning, P. E., Santen, R. J., & Hayes, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3694 · Cited by 205
Bartlett, J. M. S., Sgroi, D. C., Treuner, K., Zhang, Y., Ahmed, I., Piper, T., Salunga, R., Brachtel, E. F., Pirrie, S. J., Schnabel, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz289 · Cited by 203
Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., Liefers, G.-J., Nortier, J. W. R., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 200
Killelea, B. K., Yang, V. Q., Mougalian, S., Horowitz, N. R., Pusztai, L., Chagpar, A. B., & Lannin, D. R. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.02.011 · Cited by 197
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn005 · Cited by 197
Goss, P. E., Ingle, J. N., Pater, J. L., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6798 · Cited by 191
Nitz, U., Gluz, O., Christgen, M., Kates, R. E., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4358-6 · Cited by 189
Tang, G., Shak, S., Paik, S., Anderson, S. J., Costantino, J. P., Geyer, C. E., Mamounas, E. P., Wickerham, D. L., & Wolmark, N. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1331-z · Cited by 188
Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp033 · Cited by 186
Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3471 · Cited by 180
Masuda, N., Sagara, Y., Kinoshita, T., Iwata, H., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70373-4 · Cited by 179
Lænkholm, A.-V., Jensen, M.-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6586 · Cited by 176
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx494 · Cited by 167
Jin, H., Tu, D., Zhao, N., Shepherd, L. E., & Goss, P. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4010 · Cited by 159
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil-Ressler, S., Balic, M., Heck, D., Jakesz, R., Thaler, J., Egle, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104162 · Cited by 159
Noordhoek, I., Treuner, K., Putter, H., Zhang, Y., Wong, J., Kranenbarg, E. M., Carpentier, M. D., van de Velde, C. J. �., Schnabel, C. A., & Liefers, G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2737 · Cited by 142
Allred, D. C., Carlson, R. W., Berry, D. A., Burstein, H. J., Edge, S. B., Goldstein, L. J., Gown, A. M., Hammond, M. E. H., Iglehart, J. D., Moench, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0079 · Cited by 141
Self-citationPerez, E. A., Suman, V. J., Rowland, K. M., et al. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.047 · Cited by 137
Mouridsen, H. T., Keshaviah, A. P., Coates, A. S., Rabaglio, M., Castiglione‐Gertsch, M., Sun, Z., Thurlimann, B. J. K., Mauriac, L., Forbes, J., Paridaens, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1665 · Cited by 137
Bordeleau, L. J., Pritchard, K. I., Loprinzi, C. L., Ennis, M., Jugovic, O., Warr, D. G., Haq, R., & Goodwin, P. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9230 · Cited by 133
The ATAC Trialists' Group* (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1925 · Cited by 131
Pivot, X. B., Romieu, G., Debled, M., Pierga, J., Kerbrat, P., Bachelot, T., Lortholary, A. H., Espié, M., Fumoleau, P., Serin, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30653-1 · Cited by 130
Boekhout, A. H., Vincent, A. D., Dalesio, O., Bosch, J., Foekema-Töns, J. H., Adriaansz, S., Sprangers, S., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1298 · Cited by 123
Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B., & Rose, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3376 · Cited by 122
Joensuu, H., Kellokumpu‐Lehtinen, P., Huovinen, R., Jukkola‐Vuorinen, A., Tanner, M., Kokko, R., Ahlgren, J., Auvinen, P., Paija, O., Helle, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4639 · Cited by 118
Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression
Henry, N. L., Stearns, V., Flockhart, D. A., Hayes, D. F., & Riba, M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08040482 · Cited by 116
Yu, B., Douglas, N. C., Ferin, M., Nakhuda, G. S., Crew, K. D., Løbo, R. A., & Hershman, D. L. (2010) · Cancer · doi:10.1002/cncr.25037 · Cited by 105
Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Kashiwaba, M., Ohtani, S., Taira, N., Sakai, T., Hasegawa, Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4964-y · Cited by 101
Mastro, L. D., Mansutti, M., Bisagni, G., Ponzone, R., Durando, A., Amaducci, L., Campadelli, E., Cognetti, F., Frassoldati, A., Michelotti, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00352-1 · Cited by 99
The role of HER-2 expression in predicting response to therapy in breast cancer.
MASS, R. D. (2000) · PubMed · Cited by 92
Valachis, A., Polyzos, N. P., Coleman, R. E., Gnant, M., Eidtmann, H., Brufsky, A., Aft, R., Tevaarwerk, A. J., Swenson, K. K., Lind, P., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0261 · Cited by 85
Self-citationStemmer, S. M., Steiner, M., Rizel, S., Geffen, D. B., Nisenbaum, B., Peretz, T., Soussan‐Gutman, L., Bareket‐Samish, A., Isaacs, K., Rosengarten, O. S., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0033-7 · Cited by 85
Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay
Eppenberger‐Castori, S., Kueng, W., Benz, C. C., Caduff, R. F., Varga, Z., Bannwart, F., Fink, D., Dieterich, H., Höhl, M., Müller, H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.645 · Cited by 81
Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm566 · Cited by 67
Duffy, S., Jackson, T. L., Lansdown, M., Philips, K., Wells, M. L., Pollard, S., Clack, G., Coibion, M., & Bianco, A. (2005) · Human Reproduction · doi:10.1093/humrep/dei322 · Cited by 62
Pharmacogenetics of Endocrine Therapy for Breast Cancer
Higgins, M. J., & Stearns, V. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182545 · Cited by 54
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer
Gnant, M., Frantal, S., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balić, M., Haslbauer, F., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200162 · Cited by 51
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000234789.05150.7c · Cited by 39
Bang, S., Heo, D. S., Lee, K. H., Byun, J. H., Chang, H. M., Noh, D.-Y., Choe, K. J., Bang, Y., Kim, S. R., & Kim, N. K. (2000) · Cancer · Cited by 36
Sparano, J. A., Gray, R. J., Wood, W. C., Makower, D., Lively, T., Saphner, T. J., Keane, M., Gómez, H., Reddy, P. S., Goggins, T. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1 · Cited by 18
Self-citation
Cited by
The Role of Artificial Intelligence in Gynecologic Oncology Decision-Making: A Feasibility Study
Psilopatis, I., Sipulina, N., Stuebs, F. A., Heindl, F., Poeschke, P., Bader, S., Krueckel, A., Fasching, P. A., Beckmann, M. W., & Emons, J. (2025) · Gynecologic and Obstetric Investigation · doi:10.1159/000544751 · Cited by 8
Metadata
- Authors
- Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, A. M., Lyons, J., McCloskey, S., McShane, M., Mortimer, J., Patel, S. A., Rosenberger, L. H., Rugo, H. S., Santa-Maria, C., Schneider, B. P., Smith, M. L., Soliman, H., Stringer-Reasor, E. M., Telli, M. L., Wei, M., Wisinski, K. B., Yeung, K. T., Young, J. S., Schonfeld, R., & Kumar, R.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2024-07
- Volume
- 22
- Issue
- 5
- Pages
- 331-357
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4400800926
- Cited by
- 664
- References
- 137
- FWCI
- 101.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.